AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the ...

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...